Navidea Biopharmaceuticals Inc Volatilité

Quel est le Volatilité de Navidea Biopharmaceuticals Inc?

Le Volatilité de Navidea Biopharmaceuticals Inc est 108.80%

Quelle est la définition de Volatilité?

La volatilité ou pourcentage gamme réelle moyenne (ATRP 14) est l'ATR exprimé en pourcentage du cours de clôture.

Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.

The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.

Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets

Volatilité des entreprises dans Health Care secteur sur NYSEMKT par rapport à Navidea Biopharmaceuticals Inc

Que fait Navidea Biopharmaceuticals Inc?

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Entreprises avec volatilité similaire à Navidea Biopharmaceuticals Inc